In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleeding. Colivicchi F. Ann Intern Med 2022;175:JC22.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Colivicchi F. In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleeding. Ann Intern Med 2022;175:JC22.
PMID: 35099999